In recent trading session, Sutro Biopharma, Inc. (NASDAQ:STRO) saw 2,129,410 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $8.98 trading at $0.06 or 0.62% at recent trade assigns it a market valuation of $326.5 Million. That current trading price of STRO’s stock is at a discount of -41.98% from its 52-week high price of $12.75 and is indicating a premium of 33.18% from its 52-week low price of $6. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 125.08 Million shares which gives us an average trading volume of 155.76 Million if we extend that period to 3-months.
For Sutro Biopharma, Inc. (STRO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.7. Splitting up the data highlights that, out of 8 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 8 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.62 in the current quarter.
Sutro Biopharma, Inc. (NASDAQ:STRO) trade information
Upright in the green today for gaining 0.62%, in the last five days STRO remained trading in the green while hitting it’s week-highest on Thursday, Aug 13 when the stock touched $9.63-4 price level, adding 4.98% to its value on the day. Sutro Biopharma, Inc.’s shares saw a change of -16.82% in year-to-date performance and have moved 7.02% in past 5-day. Sutro Biopharma, Inc. (NASDAQ:STRO) showed a performance of 7.65% in past 30-days. Number of shares sold short was 767.31 Million shares which calculate 4.93 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $18.43 to the stock, which implies a rise of 105.23% to its current value. Analysts have been projecting $16 as a low price target for the stock while placing it at a high target of $20. It follows that stock’s current price would jump +122.72% in reaching the projected high whereas dropping to the targeted low would mean a loss of 78.17% for stock’s current value.
Sutro Biopharma, Inc. (STRO) estimates and forecasts
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $8.03 Million for the same. And 7 analysts are in estimates of company making revenue of $8.31 Million in the next quarter that will end in December 01, 2020. Company posted $12.28 Million and $11.3 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -34.6% while estimating it to be -26.5% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -57.1% while estimates for its earnings growth in next 5 years are of 0%
Sutro Biopharma, Inc. (NASDAQ:STRO)’s Major holders
Insiders are in possession of 21.16% of company’s total shares while institution are holding 69.52% percent of that, with stock having share float percentage of 88.18%. Investors also watch the number of corporate investors in a company very closely, which is 103 institutions for Sutro Biopharma, Inc. that are currently holding shares of the company. Sv Health Investors, LLC is the top institutional holder at STRO for having 1.82 Million shares of worth $18.61 Million. And as of March 30, 2020, it was holding 5.09% of the company’s outstanding shares.
The second largest institutional holder is Citadel Advisors LLC, which was holding about 1.55 Million shares on March 30, 2020. The number of shares represents firm’s hold over 4.32% of outstanding shares, having a total worth of $15.8 Million.
On the other hand, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Tekla Healthcare Investors are the top two Mutual Funds which own company’s shares. As of March 30, 2020, the former fund manager was holding 1285975 shares of worth $13.12 Million or 3.58% of the total outstanding shares. The later fund manager was in possession of 447.8 Thousand shares on March 30, 2020, making its stake of worth around $4.57 Million in the company or a holder of 1.25% of company’s stock.